-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Mu5gc5anEI6OL672Jen8e/aHdp2QNiSNU/5JVsXkVGwJanf3cbmlMWgou5Y+Pdcd B08TTg7kzpD0mdvRfZepXw== 0000950133-98-002134.txt : 19980529 0000950133-98-002134.hdr.sgml : 19980529 ACCESSION NUMBER: 0000950133-98-002134 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19980528 SROS: NONE GROUP MEMBERS: BB BIOTECH AG GROUP MEMBERS: BIOTECH TARGET S.A. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CV THERAPEUTICS INC CENTRAL INDEX KEY: 0000921506 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 431570294 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-47551 FILM NUMBER: 98632551 BUSINESS ADDRESS: STREET 1: 3172 PORTER DR CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 6508120585 MAIL ADDRESS: STREET 1: 3172 PORTER DRIVE CITY: PALO ALTO STATE: CA ZIP: 94304 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: DC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: 2028351882 MAIL ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 SC 13D/A 1 AMENDMENT NO. 1 TO SCHEDULE 13D 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1 )* CV THERAPEUTICS, INC. - -------------------------------------------------------------------------------- (Name of Issuer) COMMON STOCK, PAR VALUE $.001 PER SHARE - -------------------------------------------------------------------------------- (Title of Class of Securities) 126667104 - -------------------------------------------------------------------------------- (CUSIP Number) DR. ANDREAS BREMER GRAFENAUWEG 4, 6301 ZUG CH/SWITZERLAND 011-41-41-724-5959 ------------------ COPY TO: DANIEL L. GOELZER, ESQ. BAKER & MCKENZIE 815 CONNECTICUT AVENUE, N.W. WASHINGTON, D.C. 20006 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notice and Communications) MARCH 23, 1998 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ] 2 CUSIP No. 126667104 - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. BB BIOTECH AG I.R.S. Identification Nos. of above persons (entities only) NOT APPLICABLE: FOREIGN CORPORATION - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (a) (b) - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Source of Funds WC - -------------------------------------------------------------------------------- 5. Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e) - -------------------------------------------------------------------------------- 6. Citizenship or Place of Organization SWITZERLAND - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Number of 7. Sole Voting Power 0 Shares Bene- ------------------------------------------------------------ ficially by 8. Shared Voting Power 1,969,647 Owned by Each ------------------------------------------------------------ Reporting 9. Sole Dispositive Power 0 Person With ------------------------------------------------------------ 10. Shared Dispositive Power 1,969,647 - -------------------------------------------------------------------------------- 11. Aggregate Amount Beneficially Owned by Each Person reporting Person 1,969,647 - -------------------------------------------------------------------------------- 12. Check if the Aggregate Amount in Row (11) Excludes Certain shares - -------------------------------------------------------------------------------- 13. Percent of Class Represented by amount in Row (11) 17.8% - -------------------------------------------------------------------------------- 14. Type of Reporting Person HC, CO - -------------------------------------------------------------------------------- Page 2 of 5 pages 3 CUSIP No. 126667104 - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. BIOTECH TARGET S.A. I.R.S. Identification Nos. of above persons (entities only). NOT APPLICABLE: FOREIGN CORPORATION - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (a) (b) - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Source of Funds AF - -------------------------------------------------------------------------------- 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) - -------------------------------------------------------------------------------- 6. Citizenship or Place of Organization PANAMA - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Number of 7. Sole Voting Power 0 Shares Bene- ------------------------------------------------------ ficially by 8. Shared Voting Power 1,969,647 Owned by Each ------------------------------------------------------ Reporting 9 Sole Dispositive Power 0 Person With ------------------------------------------------------ 10. Shared Dispositive Power 1,969,647 - -------------------------------------------------------------------------------- 11. Aggregate Amount Beneficially Owned by Each Person reporting Person 1,969,647 - -------------------------------------------------------------------------------- 12. Check if the Aggregate Amount in Row (11) Excludes Certain shares - -------------------------------------------------------------------------------- 13. Percent of Class Represented by amount in Row (11) 17.8% - -------------------------------------------------------------------------------- 14. Type of Reporting Person CO - -------------------------------------------------------------------------------- Page 3 of 5 pages 4 ITEM 5. INTEREST IN SECURITIES OF THE ISSUER Items 5(a), 5(b) and 5(c) are hereby amended to read as follows: (a) BB Biotech may be deemed to be the indirect beneficial owner of the 1,969,647 shares of the common stock, par value $.001 per share, of CV Therapeutics, Inc. (the "Common Stock") directly beneficially owned by Biotech Target as of May 26, 1998, which represent approximately 17.8% the outstanding shares of the Common Stock. No shares of the Common Stock are directly beneficially owned by BB Biotech. To the best knowledge of BB Biotech and Biotech Target, no director or executive officer of BB Biotech or Biotech Target owns any shares of the Common Stock. (b) The number of shares of the Common Stock to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or direct the disposition, is set forth in the cover pages hereof and such information is incorporated herein by reference. BB Biotech, through its ownership of Biotech Target, may be deemed to indirectly beneficially own the shares of the Common Stock which are directly beneficially owned by Biotech Target within the meaning of Regulation 13D under the Exchange Act, and may be deemed to share with Biotech Target the power to vote, or direct the vote of, and the power to dispose of or direct the disposition of, the aggregate 1,969,647 shares of the Common Stock held directly by Biotech Target. (c) Since January 23, 1998, Biotech Target engaged in the following transactions with respect to the Common Stock. Each of these transactions was completed on the NASDAQ stock market.
===================================================================================================================== DATE TRANSACTION AMOUNT PRICE PER SHARE ============================ ============================ ============================ ============================ 3/2/98 Bought 10,000 $8.81 3/3/98 Bought 40,000 $9.00 3/4/98 Bought 30,000 $9.00 3/5/98 Bought 20,000 $9.13 3/16/98 Bought 20,000 $9.75 3/23/98 Bought 70,000 $9.88 - ---------------------------------------------------------------------------------------------------------------------
Page 4 of 5 pages 5 SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. BB BIOTECH AG Date: May 26, 1998 By: /s/ Hans-Joerg Graf ---------------------------- Name: Hans-Joerg Graf Signatory Authority Date: May 26, 1998 By: /s/ Dr. Victor Bischoff ---------------------------- Name: Dr. Victor Bischoff Vice Chairman and Director BIOTECH TARGET S.A. Date: May 26, 1998 By: /s/ Dr. Andreas Bremer ---------------------------- Name: Dr. Andreas Bremer Signatory Authority Date: May 26, 1998 By: /s/ Dr. Anders Hove ---------------------------- Name: Dr. Anders Hove Signatory Authority Page 5 of 5 pages -----END PRIVACY-ENHANCED MESSAGE-----